ASND (Ascendis Pharma A/S) Rega marang bathi mangsa ngarep

How does the reliance on contract manufacturing and partner logistics impact the valuation of Ascendis Pharma A/S (ASND)? The business's forward P/E multiple provides the answer, and the current parameter is 25.50. The asset is considered a defensive asset, as demand for the treatment of endocrine pathologies is independent of crises. The company's environmental footprint is minimal and limited by strict chemical controls in Danish laboratories.

A forward P/E ratio is used to assess the investment attractiveness of Ascendis Pharma A/S (ASND). The company's current forward P/E is calculated as the ratio of the share price to the expected annual net income. This indicator determines the degree of optimism priced in regarding the commercialization of the TransCon platform. A decline in this metric to historical lows may indicate an undervaluation of the potential for rare injections. The fundamental value of the business here depends on the pace of replacement for daily therapy.